Table 3 HIV clinical characteristic and HPV prevalences among perinatally and non-perinatally HIV-infected, sexually experienced women
Non-perinatally infected N = 200 n (%) | Perinatally infected N = 65 n (%) | p-value* | |
|---|---|---|---|
HIV clinical characteristics | |||
CD4 count (cells/mm3) | 0.71 | ||
< 200 | 5 (2.5) | 0 (0.0) | |
200–349 | 32 (16.1) | 9 (13.9) | |
350–499 | 37 (18.6) | 14 (21.5) | |
≥ 500 | 125 (62.8) | 42 (64.6) | |
Viral load (copies/mL) | 0.06 | ||
≤ 400 | 186 (95.9) | 57 (89.1) | |
> 400 | 8 (4.1) | 7 (10.9) | |
Age of ART initiation (years) | < 0.001 | ||
0–4 | 0 (0.0) | 7 (10.8) | |
5–9 | 0 (0.0) | 34 (52.3) | |
10–14 | 0 (0.0) | 21 (32.3) | |
≥ 15 | 199 (100.0) | 3 (4.6) | |
HPV type category | |||
Any HPV | 177 (88.5) | 55 (84.6) | 0.41 |
Any HR-HPV | 159 (79.5) | 48 (73.9) | 0.34 |
Any LR-HPV | 132 (66.0) | 42 (65.2) | 0.84 |
Quadrivalent vaccine | 72 (36.0) | 27 (41.5) | 0.42 |
HR-HPV16/18 | 50 (25.0) | 19 (29.2) | 0.50 |
LR-HPV6/11 | 33 (16.5) | 14 (21.5) | 0.36 |
Number of HPV types detected (among HPV+) | |||
1 | 30 (17.0) | 12 (21.8) | 0.43 |
2–4 | 76 (42.9) | 26 (47.3) | |
≥ 5 | 71 (40.1) | 17 (30.9) | |